Greenwich Investment Management Inc., a financial management company, has reduced its holdings in Oaktree Specialty Lending Co. (NASDAQ:OCSL) by 6.5% in the third quarter, selling 56,415 shares and leaving them with 815,871 shares. Oaktree Specialty Lending accounts for 13.0% of Greenwich Investment Management Inc.'s holdings, making it their second-largest position. Other large investors have also recently bought and sold shares of the company. Oaktree Specialty Lending's stock is currently trading at $19.72, with a 50-day simple moving average of $20.44 and a two-hundred day simple moving average of $20.05. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.61. Oaktree Specialty Lending has announced a quarterly dividend of $0.55 per share, payable on March 29th to shareholders of record on March 15th. The company's payout ratio is currently 145.70%. Director Phyllis R. Caldwell purchased 2,000 shares of Oaktree Specialty Lending stock at an average price of $20.07 per share.
Kent Lake Capital LLC has increased its stake in The Oncology Institute, Inc. (NASDAQ:TOI) by 492.3% in the 4th quarter, purchasing an additional 901,956 shares. The firm now owns 1,085,171 shares of the company's stock, representing approximately 1.47% of the total shares. Other institutional investors have also recently added to or reduced their stakes in the stock. The stock of The Oncology Institute, Inc. is currently trading at $1.50 per share. The company has a market capitalization of $110.63 million and a price-to-earnings ratio of -1.63. Jefferies Financial Group has initiated coverage on the stock with a 'buy' rating and a price target of $2.50. Insiders have sold 62,780 shares of the company's stock in the last 90 days, representing 13.10% of the total shares.
Vinva Investment Management Ltd purchased 37,317 shares of A. O. Smith Co. (NYSE:AOS) during the fourth quarter, valued at approximately $3,069,000. Several other hedge funds and institutional investors have also recently bought and sold shares of the stock. A. O. Smith Co. has a market capitalization of $11.89 billion, a P/E ratio of 21.01, and a beta of 1.18. The company reported $1.00 earnings per share for the last quarter, beating the consensus estimate of $0.99. A. O. Smith Co. paid a quarterly dividend of $0.32 per share on May 15th, representing a dividend yield of 1.58%. The stock has a consensus rating of 'Hold' and a consensus price target of $90.67.
1832 Asset Management L.P. decreased its stock position in Omnicom Group Inc. (NYSE:OMC) by 28.0% during the fourth quarter, selling 8,647 shares and leaving them with 22,218 shares. The value of their holdings was $1,922,000 at the end of the quarter. Other institutional investors and hedge funds also bought and sold shares of OMC. Director Linda Johnson Rice sold 453 shares of the company's stock on May 3rd at an average price of $92.68, for a total transaction of $41,984.04. The stock is currently rated as a 'Moderate Buy' with an average price target of $104.40. Omnicom Group Inc. is a business services provider that offers advertising, marketing, and corporate communications services. The company reported earnings per share of $1.67 for the last quarter, beating analysts' estimates of $1.52. Omnicom Group also announced a quarterly dividend of $0.70 per share, payable on July 9th to shareholders of record on June 10th.
Oppenheimer & Co. Inc. lowered its stake in shares of GSK plc (NYSE:GSK) by 24.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,599 shares of the pharmaceutical company's stock after selling 22,195 shares during the period. Oppenheimer & Co. Inc.'s holdings in GSK were worth $2,579,000 as of its most recent filing with the Securities & Exchange Commission. A number of other large investors have also made changes to their positions in GSK. Crossmark Global Holdings Inc. grew its position in GSK by 2.9% during the 4th quarter. Crossmark Global Holdings Inc. now owns 30,996 shares of the pharmaceutical company's stock worth $1,149,000 after purchasing an additional 887 shares during the period. Lake Street Advisors Group LLC acquired a new stake in shares of GSK during the 4th quarter worth approximately $201,000. Armistice Capital LLC increased its holdings in GSK by 670.5% in the 4th quarter. Armistice Capital LLC now owns 2,196,000 shares of the pharmaceutical company's stock valued at $81,384,000 after purchasing an additional 1,911,000 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in GSK by 4.2% in the 4th quarter. The Manufacturers Life Insurance Company now owns 1,031,667 shares of the pharmaceutical company's stock valued at $38,234,000 after purchasing an additional 41,632 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its position in GSK by 23.1% in the 4th quarter. Jones Financial Companies Lllp now owns 1,633 shares of the pharmaceutical company's stock valued at $61,000 after buying an additional 306 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds. GSK plc has a one year low of $33.67 and a one year high of $45.92. The company has a 50-day simple moving average of $42.61 and a 200-day simple moving average of $40.74. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87. The firm has a market capitalization of $85.41 billion, a PE ratio of 14.93, a price-to-earnings-growth ratio of 1.26 and a beta of 0.66. GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.